In this respect, in a phase 2 clinical trial GBM patients with unmethylated MGMT promoter were administered with a single dose of autologous CD34+-enriched hematopoietic stem and progenitor cells (HSPCs) exposed to transduction with a 3rd generation lentivirus mediating myeloid-specific IFN-α2 expression (NCT03866109). Here, MGMT is linked to glioblastoma.